Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913529
rs121913529
0.800 GeneticVariation UNIPROT

dbSNP: rs121913240
rs121913240
0.710 GeneticVariation UNIPROT

dbSNP: rs121913527
rs121913527
0.700 GeneticVariation UNIPROT

dbSNP: rs770248150
rs770248150
0.700 GeneticVariation UNIPROT

dbSNP: rs121913529
rs121913529
0.800 GeneticVariation BEFREE Recent evidence associates the codon 12 valine-for-glycine (G12V) mutant Ki-Ras protein with higher stage and increased lethality of colorectal carcinomas, while the codon 12 aspartate-for-glycine (G12D) Ras mutation shows no such association. 10398103

1999

dbSNP: rs112445441
rs112445441
0.100 GeneticVariation BEFREE Furthermore, HNPCC CRCs had more G13D mutations than MSS (P < 0.0001), MSI-H (P = 0.02) or MSI-H tumours with hMLH1 hypermethylation (P = 0.03). 15294875

2004

dbSNP: rs112445441
rs112445441
0.100 GeneticVariation BEFREE We aimed to study proliferation and survival effects induced by BRAF inhibition in MSI CRC cell lines harbouring distinct genetic backgrounds (BRAF V600E or KRAS G13D). 18098337

2008

dbSNP: rs121913529
rs121913529
0.800 GeneticVariation BEFREE The aim of our study was to evaluate the combined effects of MSI, BRAF(V600E) and specific KRAS mutation (Gly → Asp; G12D, Gly → Asp, G13D; Gly → Val; G12V) on prognosis in 404 sporadic and 94 hereditary CRC patients. 20162668

2010

dbSNP: rs121913529
rs121913529
0.800 GeneticVariation BEFREE In contrast, in KRAS-mutant CRC cells (DLD-1(G13D) and SW480(G12V)), KRAS knocked-down by KRAS-siRNA led to ERCC1 upregulation and increased oxaliplatin resistance. 23209813

2012

dbSNP: rs121913529
rs121913529
0.800 GeneticVariation BEFREE KRAS codon 12 mutations (in particular, c.35G>T), but not codon 13 mutations, are associated with inferior survival in BRAF wild-type colorectal cancer. 22753589

2012

dbSNP: rs121913238
rs121913238
0.010 GeneticVariation BEFREE Bevacizumab-based treatment in colorectal cancer with a NRAS Q61K mutation. 23400451

2013

dbSNP: rs112445441
rs112445441
0.100 GeneticVariation BEFREE Our finding that KRAS codon 13 mutations (in particular G13D) are associated with inferior survival in BRAF wild-type CRCs in Chinese patients was not reported thus far. 25367198

2014

dbSNP: rs112445441
rs112445441
0.100 GeneticVariation BEFREE We have investigated Ca(2+) signalling in two human colorectal cancer cell lines and their isogenic derivatives in which the allele encoding oncogenic K-Ras (G13D) was deleted by homologous recombination. 24522186

2014

dbSNP: rs61764370
rs61764370
0.030 GeneticVariation BEFREE A PubMed search was conducted to identify all studies reporting on KRAS let-7 microRNA-binding site polymorphism (LCS6; rs61764370) and colorectal cancer outcome. 24890702

2014

dbSNP: rs712
rs712
0.030 GeneticVariation BEFREE Stratified analyses revealed that CRC patients with the let-7 KRAS rs712 TT genotype were more likely to have clinical stage III or IV disease (OR = 3.29, 95% CI, 1.32-8.20) and distant metastasis (OR = 4.70, 95% CI, 1.81-12.25). 23975373

2014

dbSNP: rs397517040
rs397517040
0.010 GeneticVariation BEFREE We detected a GGT insertion between codons 12 and 13 (c.36_37insGGT;p.G12_G13insG) in a CRC patient. 24594115

2014

dbSNP: rs121913529
rs121913529
0.800 GeneticVariation BEFREE The increased cell survival, invasion, intravasation, and specific molecular regulation observed in KRas G12V tumors is consistent with the higher aggressiveness observed in patients with CRC expressing this oncogene. 25359494

2015

dbSNP: rs112445441
rs112445441
0.100 GeneticVariation BEFREE Higher metastatic efficiency of KRas G12V than KRas G13D in a colorectal cancer model. 25359494

2015

dbSNP: rs121913530
rs121913530
0.040 GeneticVariation BEFREE KRAS exon 2 analysis was performed on 2239 CRC and 2.2% harbored the c.34G>T transversion. 26056087

2015

dbSNP: rs61764370
rs61764370
0.030 GeneticVariation BEFREE A single-nucleotide polymorphism (rs61764370, T > G base substitution) in the let-7 complementary site 6 (LCS-6) of KRAS mRNA has been shown to predict prognosis in early-stage colorectal cancer (CRC) and benefit from anti-epidermal growth factor receptor monoclonal antibodies in metastatic CRC. 26162609

2015

dbSNP: rs121913529
rs121913529
0.800 GeneticVariation BEFREE Moreover, comparison of the survival of patients with tumors harboring G12V/A KRAS mutations with those harboring wild-type KRAS gene revealed that G12V/A KRAS mutations are prognostic biomarker for inferior PFS and OS in patients with mCRC treated with bevacizumab in univariate as well as multivariable analyses. 26662311

2016

dbSNP: rs121913529
rs121913529
0.800 GeneticVariation BEFREE The dominant oncogenic mutations of KRAS are single amino acid substitutions at codon 12, in particular G12D and G12V present in 60% to 70% of pancreatic cancers and 20% to 30% of colorectal cancers. 26701267

2016

dbSNP: rs112445441
rs112445441
0.100 GeneticVariation BEFREE Recruitment, particularly of patients with the rare G13D mutation, will demonstrate the ability for international collaboration to run prospective trials in small colorectal cancer molecular subgroups. 27246726

2016

dbSNP: rs112445441
rs112445441
0.100 GeneticVariation BEFREE To accomplish this, we first carried out an in silico analysis of RNA-seq databases and found that the distribution of alternative splicing isoforms of genes RPL13, HSP90B1, ENO1, EPDR1 and ZNF518B was altered in human CRC cell lines carrying the G13D KRAS mutation when compared to cell lines carrying wild-type KRAS. 27805251

2016

dbSNP: rs121913240
rs121913240
0.710 GeneticVariation BEFREE Review of colorectal carcinomas with known KRAS and NRAS genotype revealed that none of 62 wild-type tumors or 47 mutants other than Q61R were SP174 positive. 28353383

2017